DDInter1291 DDInter1628
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Nifedipine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Nifedipine {u} (Compound) upregulates {v} (Gene) C10orf2
C10orf2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Nifedipine {u} (Compound) downregulates {v} (Gene) SLC35A1
SLC35A1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Nifedipine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Nifedipine {u} (Compound) upregulates {v} (Gene) C10orf2
C10orf2 {u} (Gene) is regulated by {v} (Gene) ZFX
ZFX {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Nifedipine {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Nifedipine {u} (Compound) downregulates {v} (Gene) SLC35A1
SLC35A1 {u} (Gene) regulates {v} (Gene) MAP3K7
MAP3K7 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Nifedipine {u} (Compound) downregulates {v} (Gene) SLC25A4
SLC25A4 {u} (Gene) interacts with {v} (Gene) PRKCE
PRKCE {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Nifedipine {u} (Compound) downregulates {v} (Gene) CHMP4A
CHMP4A {u} (Gene) is regulated by {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Nifedipine {u} (Compound) downregulates {v} (Gene) CASC3
CASC3 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Nifedipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Nifedipine (Compound) upregulates C10orf2 (Gene) and C10orf2 (Gene) is upregulated by Ruxolitinib (Compound)
Nifedipine (Compound) downregulates SLC35A1 (Gene) and SLC35A1 (Gene) is downregulated by Ruxolitinib (Compound)
Nifedipine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Nifedipine (Compound) upregulates C10orf2 (Gene) and C10orf2 (Gene) is regulated by ZFX (Gene) and ZFX (Gene) is upregulated by Ruxolitinib (Compound)
Nifedipine (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Nifedipine (Compound) downregulates SLC35A1 (Gene) and SLC35A1 (Gene) regulates MAP3K7 (Gene) and MAP3K7 (Gene) is bound by Ruxolitinib (Compound)
Nifedipine (Compound) downregulates SLC25A4 (Gene) and SLC25A4 (Gene) interacts with PRKCE (Gene) and PRKCE (Gene) is bound by Ruxolitinib (Compound)
Nifedipine (Compound) downregulates CHMP4A (Gene) and CHMP4A (Gene) is regulated by JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Nifedipine (Compound) downregulates CASC3 (Gene) and CASC3 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)